The MEDITWIN consortium was announced on December 11, 2023, in
the presence of French President Emmanuel Macron. More details were
presented at the PariSanté Campus on December 14 in the presence of
French Minister Delegate for Industry Roland Lescure. The
consortium is made up of seven University Hospital Institutes
(IHUs), Nantes University Hospital (CHU), Inria, startups and
Dassault Systèmes. MEDITWIN will offer virtual twins for medical
practice, helping to improve the quality of care for safer, more
accessible healthcare for all.
The MEDITWIN project will offer personalized virtual twins of
organs, metabolism and cancer, for better diagnosis and treatment.
In particular, MEDITWIN will enable doctors to simulate future
scenarios for a patient.
Seven new medical practices will be developed from the virtual
twins, in neurology, cardiology and oncology. This will result in
seven "virtual healthcare products" that will be deployed on a
sovereign industrial cloud platform.
The MEDITWIN project leverages the expertise of world-class
partners in each of the fields covered, around the 14 founding
members of this consortium: Dassault Systèmes, as the industrial
leader of the consortium; seven University Hospital Institutes at
the highest level of medical and scientific excellence; Nantes
University Hospital via l’institut du thorax; startups inHEART,
Codoc, Qairnel and Neurometers; and Inria through 11 project teams
involved in this project.
Virtual twins have become an indispensable asset in the
aeronautics and mobility industries, where virtualization has
enabled considerable progress in terms of safety, quality,
ecological footprint and cost-effectiveness. MEDITWIN builds on the
experience accumulated by the partners over many years in the field
of virtual twins for healthcare, such as the Living Heart
initiative by Dassault Systèmes (link), the Living Brain (link), as
well as the activities of the PEPR digital health program
co-directed by Inria and INSERM, for example.
MEDITWIN will enable the industrialization, clinical validation
and standardization of these innovations, so that these
technologies can be deployed in a standardized way and benefit as
many people as possible. The best standards of care will be
incorporated into virtualized experiences made accessible
worldwide, setting a new benchmark for quality in healthcare and
providing a decisive learning ground for progress in medical
science.
The benefits of virtual twins will be assessed for medical
teams, patients, and the healthcare system, notably in terms of
improving the efficiency of care, quality of multidisciplinary
decision-making, and effectiveness and safety of medical practices
and interventions.
In practice, the MEDITWIN initiative will be developed over five
years, from 2024 to 2029. The partners' investment in this project
will be financially supported by the French government as part of
the “France 2030” plan.
Partner quotes
Bernard Charlès, Chairman of Dassault Systèmes “Virtual
twins have successfully enabled the industrial world to transform
itself more sustainably. Today, this technology is opening up new
possibilities for healthcare by revealing the secrets of the human
body - by understanding and representing the invisible. For 40
years, Dassault Systèmes has been a pioneer in virtual twins, and
we can apply our knowledge and know-how to transform medical
practice. The MEDITWIN public-private alliance is a major step
forward, mobilizing the best of medicine, science and technology to
serve future healthcare. The virtual twin is already a reality, and
MEDITWIN will help standardize and disseminate it worldwide to
benefit millions of patients.”
Bruno Sportisse, CEO of Inria “Building an active digital
ecosystem can only make France a European leader in digital
healthcare innovation. In line with their strategic partnership
signed in 2021, Inria and Dassault Systèmes are actively
collaborating in the field of virtual twins in healthcare, with an
aligned vision of the challenges of sovereignty and the digital
transformation of healthcare. Supported by France 2030, the
MEDITWIN project, resulting from ambitious collaboration between
Dassault Systèmes, Inria and IHU France, demonstrates the
commitment of these players to building a French industry at the
forefront of emerging healthcare issues, all for the benefit of
patients.”
Fabrice André, CEO of IHU PRISM of Gustave Roussy “The
MEDITWIN consortium is in line with PRISM's vision of developing
cancer avatars to model biology at the patient level and tailor
personalized therapies. PRISM will also benefit from the expertise
of the other IHUs, and will be working closely with them to develop
interdisciplinary projects.”
Pierre JAIS, CEO of IHU LIRYC “Combining 7 IHUs, Inria
and Dassault Systèmes, MEDITWIN is a remarkable public/private
collaboration. This unique project opens a new era for scaled and
automated preventive medicine, so critical for patients and
immensely cost effective. Finally, it offers French doctors and
researchers the opportunity of relying on a global industry
champion in digital health for future medical research.”
Pr. Didier Mutter, CEO, IHU Strasbourg “Virtual twins
will be essential elements in the medicine of the future, as they
will enable treatments to be simulated to provide patients with the
best possible results. MEDITWIN is an exceptional project in terms
of its ambition and the challenges to be met. It's also a premiere
for the IHU France alliance, uniting a multidisciplinary biomedical
research capability that has no parallel anywhere in the world. For
IHU Strasbourg, it will be a powerful catalyst for improving the
minimally invasive management of metastatic colorectal cancer, in
close collaboration with two of its historical founders, Inria and
the University Hospitals of Strasbourg.”
Pr. Michel Paques, IHU FOReSIGHT, head of the ophthalmology 4
department and Director of the Clinical Investigation Center at the
15-20 national hospital “The integration of the FOReSIGHT IHU
into the MEDITWIN consortium will enable the large-scale
development of retinal microcirculation twins, enabling
personalized detection and monitoring of cerebral and
cardiovascular diseases in quantitative terms. This will be the
first development of a quantitative microcirculatory biomarker. The
FOReSIGHT IHU has developed expertise in innovative microvascular
imaging using retinal imaging with adaptive optics, a technique in
which France is a leader, with the help of French high-tech
companies and research institutes. This approach, unique in the
world, will be strengthened with Dassault Systèmes through the
development of algorithms based in particular on AI to extract
morphometric information from large retinal surfaces. The
integration of these measurements into biomarkers that can be used
directly by practitioners represents a major challenge for the
transfer from the research laboratory to the consulting room.”
Pr. Stanislas Lyonnet, CEO of Institut Imagine “Institut
Imagine is proud to have been one of the initiators of the
strategic partnership between Dassault Systèmes and Alliance IHU
France on virtual twins. We are delighted to put our medical and
research excellence in the field of rare diseases at the service of
the MEDITWIN project. The first project, developed with Dassault
Systèmes and INRIA, concerns cardiology, with a peri-surgical
decision support system designed to drastically reduce the
mortality rate of newborns suffering from congenital heart disease
(Hypoplastic Left Heart Syndrome) thanks to a personalized virtual
twin of the cardiovascular system. Our second project, developed in
partnership with Dassault Systèmes and startup CODOC, concerns
pediatric neurology, with a tool for managing the Multidisciplinary
Board Meeting that uses a virtual twin of patients to aid medical
decision-making and management of rare epilepsies, in particular
Dravet syndrome. These two projects offer significant opportunities
for researchers and doctors, who will be able to visualize, test,
understand, and predict before experimenting on patients.”
Pr. Alexis Brice, CEO of Paris Brain Institute, IHU ICM
“We are delighted to collaborate closely with Dassault Systèmes and
Inria within the IHU Alliance. We aim to structure an ecosystem of
innovation in healthcare from which the medicine of tomorrow will
emerge. The digital twin embodies the ambitions of the Institute's
research: to streamline the use of health data at different scales,
to model and predict the evolution of diseases, to diagnose early,
and to build personalized medicine on a solid and reliable
foundation. Within MEDITWIN, Paris Brain Institute will contribute
its expertise in detecting Alzheimer's disease, vascular dementia
and epilepsy, and in analyzing data from patient cohorts.”
Pr. Stéphane Hatem, CEO of IHU ICAN and Director of the UMR
1166 Research Unit on Cardiovascular and Metabolic Diseases
“Virtual twin technology opens up possibilities for novel precision
and preventive medicine for cardiometabolic diseases. Its goal is
to predict the personal future risk of developing a cardiovascular
disease, based on individual risk profiles, especially the genomic
signature. Such an ambition requires changing the scale of today’s
research that will be achieved through the MEDITWIN project led by
Dassault Systèmes and with all its partners on board.”
Pr. Bertrand Cariou, Director of l’institut du thorax, CHU de
Nantes “Nantes University Hospital, via ‘l’institut du thorax’,
in collaboration with Dassault Systèmes engineers, will carry out
developments aimed at improving the prediction of cardiovascular
accidents, which represent the leading cause of mortality in
industrialized countries. To achieve this goal, the researchers
will use data from the SAFIR cohort, an outcome of the CHOPIN
(CHOlesterol Personalized INnovation) nationwide translational
research project, on patients with familial hypercholesterolemia
with or without cardiovascular disease. This pilot study in a very
high-risk cardiovascular population will combine clinical,
multi-omics and imaging data to create a virtual twin model, which
will then be validated in a larger cardiovascular population.”
Todor Jeliaskov, CEO of inHEART “At inHEART, we are
excited to be part of MEDITWIN and on the forefront of the digital
health transformation. Within MEDITWIN, inHEART will focus on the
prevention of Sudden Cardiac Death, which takes more than 800,000
lives each year. We need to move our healthcare systems from
reacting to acute complications to preventing complications.
Digital technologies and Artificial Intelligence are accelerating
this process.”
Arthur Delapalme, Co-founder and CEO of CODOC “The
MEDITWIN project has succeeded in bringing together the medical
expertise of several different University Hospital Institutes. In
our view, this multidisciplinary approach is a fruitful way of
accelerating research and rapidly bringing the benefits of
innovations to patients. As CODOC, we are very proud to build one
of the seven virtual twins of this project.”
Stanley Durrleman, CEO of QAIRNEL “At Qairnel, we're
proud to be part of the MEDITWIN project. Our virtual twins
simulate the evolution of a patient in the early stages of
Alzheimer's disease. The project will enable us to put these
technologies into the hands of practitioners, to propose
personalized management schemes and therapeutic strategies. This
will enable us to respond to one of the major public health
challenges of the 21st century.”
Lionel Naccache, Co-Founder of Neurometers “Neurometers
aims to generalize the medical use of the electroencephalogram
(EEG) to quantify the cerebral signatures of consciousness and
cognition. Initially developed in healthy subjects and
non-communicative patients, with highly original results validated
in numerous scientific publications, we have more recently
discovered and reported that this approach could prove highly
promising in the field of neurodegenerative diseases that impair
cognition, such as Alzheimer's disease. For the first time, direct
measures of cognitive functioning could be integrated into routine
clinical monitoring of patients, complementing neuropsychological
tests and measures of cerebral atrophy. This approach could also
make it possible to evaluate the efficacy of new therapies. Our
participation in the MEDITWIN project is aimed at improving the
quality of our algorithms by analyzing a large cohort of patient
EEG recordings in an evolutionary manner.”
###
About France 2030
The France 2030 investment plan:
- Reflects a double ambition: sustainably transform key
sectors of our economy (energy, automotive, aeronautics or space)
through technological innovation, and position France not only as a
player, but also as a leader in the world of tomorrow. From basic
research, to the emergence of an idea to the production of a new
product or service, France 2030 supports the entire life cycle of
innovation until its industrialization.
- Is unpublished by its magnitude: €54 billion will be
invested to ensure that our companies, universities and research
organizations are fully successful in their transitions in these
strategic sectors. The challenge: to enable them to respond
competitively to the ecological and attractiveness challenges of
the coming world, and to bring out the future champions of our
sectors of excellence. France 2030 is defined by two cross-cutting
objectives consisting in dedicating 50% of its spending to the
decarbonization of the economy, and 50% to emerging players, who
are the bearers of innovation without spending that is unfavorable
to the environment (in the sense of the Do No Significant Harm
principle).
- Will be implemented collectively: designed and deployed
in consultation with economic, academic, local and European
stakeholders to determine their strategic orientations and flagship
actions. Project leaders are invited to submit their application
via open, demanding and selective procedures to benefit from the
support of the State.
- Is led by the General Secretariat for Investment on
behalf of the Prime Minister and implemented by the French Agency
for Ecological Transition (ADEME), the French National Research
Agency (ANR), Bpifrance and the Banque des Territoires.
More information on: france2030.gouv.fr | @SGPI_avenir
###
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for
human progress. We provide business and people with collaborative
virtual environments to imagine sustainable innovations. By
creating virtual twin experiences of the real world with our
3DEXPERIENCE platform and applications, our customers can redefine
the creation, production and life-cycle-management processes of
their offer and thus have a meaningful impact to make the world
more sustainable. The beauty of the Experience Economy is that it
is a human-centered economy for the benefit of all –consumers,
patients and citizens. Dassault Systèmes brings value to more than
300,000 customers of all sizes, in all industries, in more than 150
countries. For more information, visit www.3ds.com Press contact:
arnaud.malherbe@3ds.com
About INRIA
Inria is the French national research institute for digital
science and technology. World-class research, technological
innovation and entrepreneurial risk are its DNA. In 220 project
teams, most of which are shared with major research universities,
more than 3,900 researchers and engineers explore new paths, often
in an interdisciplinary manner and in collaboration with industrial
partners to meet ambitious challenges. As a technological
institute, Inria supports the diversity of innovation pathways:
from open source software publishing to the creation of
technological startups (Deeptech). Press contact:
laurence.goussu@inria.fr / magalie.quet@inria.fr
About IHU PRISM and Gustave Roussy
IHU Prism is based on a transformative vision of cancer care. It
is supported by a consortium of five partners: Gustave Roussy,
Université Paris-Saclay, CentraleSupelec, Inserm and Unicancer. Its
aim is to better understand the biology of each patient's cancer,
and to identify those with the most aggressive tumors as soon as
they are diagnosed, in order to offer them a different care
pathway, based on innovation, to maximize the chances of a
therapeutic response. To achieve this, it relies on innovative
tools and methodologies such as circulating marker analysis,
artificial intelligence and organoids. Prism also aims to change
the way in which cancer is viewed and classified, from an
organ-based approach to a molecular one. https://prism.center/
Press contact: claire.parisel@gustaveroussy.fr
About IHU Liryc
Liryc is the only institute of its kind in the world dedicated
to heart rhythm disorders. Liryc is committed to 4 missions:
research, innovation, care and training. The aim is to gain a
better understanding of the mechanisms behind these diseases, to
develop therapeutic and diagnostic tools, to treat patients more
effectively and to pass on the expertise acquired. Liryc brings
together researchers, doctors, engineers and mathematicians from
all over the world. In a unique technological environment and a
dynamic ecosystem, Liryc is helping to invent the therapeutic tools
of tomorrow, to meet this major public health challenge. It is one
of seven university hospital institutes (IHU) created by the French
government as part of the "Investissements d'Avenir" program, with
the aim of boosting medical research and innovation in France. Its
founders are the University of Bordeaux, the University Hospital of
Bordeaux, Inria and the Nouvelle-Aquitaine region. Press contact:
manon.hans@ihu-liryc.fr - 06 23 29 70 20
About IHU Strasbourg
(www.ihu-strasbourg.eu)
The IHU Strasbourg is a multidisciplinary institute dedicated to
the creation and dissemination of innovative image-guided therapies
for optimized, safe, and personalized patient care. Its goal is to
establish a new standard of care for surgical patients, considering
their entire treatment itinerary from preparation for surgery to
their return to the norm, offering them the best possible quality
of life. The Institute's missions focus on four key pillars:
patient care, translational research, education and technology
transfer. These missions encompass improving patients' quality of
life, researching new treatments, developing innovative devices,
and training and disseminating knowledge to support the ongoing
evolution of the medicine of the future. Press contact:
presse@ihu-strasbourg.eu
About IHU FOReSIGHT
Labeled IHU in 2019, the IHU FOReSIGHT aims to bring about the
care of tomorrow in ophthalmology by accelerating research and
access to therapeutic innovations. It was founded by the 15-20
National hospital, Sorbonne University, Inserm and the Fondation
Voir et Entendre. It brings together expert centers in
ophthalmology including the 15-20 National hospital and the Vision
Institute of Paris, an international research center entirely
dedicated to fundamental and translational research on vision
diseases. Press contact: sylvie.jumel@institut-vision.org
About Institut Imagine
Located on the campus of the Necker-Enfants malades hospital,
the Institut Imagine is a world leader in research, care and
teaching on genetic diseases. Its unique architecture, designed by
Jean Nouvel and Bernard Valéro, brings together 1,000 researchers,
physicians, teacher-researchers, engineers and health care
personnel in a single location to work with patients, with the
ambition of accelerating research and diagnosis and therapeutic
innovation to change the lives of families affected by genetic
diseases. The Institut Imagine has been certified “Institut
hospitalo universitaire” (IHU), in 2011 and 2019 and an “Institut
Carnot”, in 2020. It is supported by six founding members,
including AP-HP, Inserm and Université Paris Cité, as well as by
private partners and patrons. Every day in France, 64 babies are
born with a genetic disease. Nearly 8,000 genetic diseases affect
more than 3 million people, of which nearly one in two is
undiagnosed and more than 8 in 10 have no dedicated treatment.
Faced with this public health emergency, the challenge is twofold:
to diagnose and to cure.
www.institutimagine.org
Press Contact: marie.de-bazelaire@institutimagine.org
About Institut du Cerveau
Created in 2010, Paris Brain Institute is a leading scientific
and medical research center dedicated to the study of the brain and
the discovery of new treatments for diseases of the nervous system.
Its innovative model brings together patients, doctors,
researchers, and entrepreneurs with a common goal: to transform
fundamental discoveries into therapeutic solutions via a
translational and interdisciplinary approach. Located in Paris at
the heart of the Pitié-Salpêtrière Hospital – the largest neurology
center in Europe – Paris Brain Institute includes over 800
international experts in 27 research teams, ten cutting-edge
technological platforms, a clinical investigation center, a
training organization, a living lab, and a business incubator. It
is based on the association of a joint research unit (Sorbonne
University, Inserm, and CNRS) and a private foundation recognized
as being of public utility, the ICM Foundation, in partnership with
Assistance Publique–Hôpitaux de Paris. institutducerveau-icm.org
Press contact: presse@icm-institute.org
About IHU ICAN
Created in 2011, located at the Pitié Salpêtrière Hospital, the
Foundation for Innovation in CArdiometabolism and Nutrition (IHU
ICAN) is a “Hospital-University Institute” and a center of
excellence for translational research on cardiometabolic diseases
such as diabetes, obesity, fatty liver disease (MASH), heart and
vascular diseases. Our goal is to contribute to the emergence of a
new personalized medicine that integrate the determinants that
contribute to the risk of developing cardiometabolic diseases. With
the support of its founders, the Greater Paris University Hospitals
(AP-HP - Assistance Publique- Hôpitaux de Paris), the National
Institute for Health and Medical Research (Inserm - Institut
national de la santé et de la recherche médicale) and Sorbonne
University (SU), ICAN has structured cutting-edge scientific
platforms and unique expertise for translational research with a
strong focus on multi-omic, new clinical imaging, data integration
and artificial intelligence. IHU ICAN key figures: 170 physicians,
220 researchers, 50 active clinical trials, 6 rare disease
reference centers, 4 innovative care pathways, over 6,000
scientific publications and overall more than 42,000 patients
included in cohorts, registries and clinical trials. Today, ICAN is
one of Europe's leading institutes for cardiovascular, metabolic
and nutritional diseases, bringing together teams of basic and
clinical researchers. Press contact: Francine Trocmé -
f.trocme@ihuican.org
About CHU de Nantes
In the heart of Nantes, the University Hospital has nearly
13,000 employees who contribute to the promotion of the values of
the public hospital service: equality, continuity, neutrality, and
adaptability. With its nine establishments, the University Hospital
of Nantes constitutes a center of excellence, healthcare recourses,
and reference at both regional and interregional levels, while
providing routine and local care to the 800,000 inhabitants of the
Nantes/Saint-Nazaire metropolis. Located on the south bank of the
Loire, a new hospital will come to fruition in 2027. It will be the
foundation of the future health district, a project of European
dimension. Created in 2004, l'institut du thorax is a translational
research structure (CHU de Nantes/Inserm/CNRS/Nantes Université)
dedicated to cardiac, vascular and metabolic diseases, combining
research, clinical investigation and advanced training within a
single organization. It aims at identifying genetic risk-factors,
biomarkers and therapeutic targets to improve patient care, based
on large, finely-documented bio-collections directly inspired by
real-life patient experience and unmet medical needs. Press
contact: Zakaria Gambert, zakaria.gambert@chu-nantes.fr, 07 77 25
95 47 Florane Pasquier, florane.pasquier@chu-nantes.fr, 02 53 48 28
11
About inHEART
inHEART is a deep-tech healthcare startup based in Pessac,
France. It’s a spin-off from INRIA, CHU de Bordeaux and Université
de Bordeaux. The company develops web-based SaaS solutions for
cardiologists by utilizing AI. inHEART leverages cardiac images and
electrocardiograms uploaded by the physician to deliver a digital
twin of the patient’s heart for cardiac arrhythmia treatment
support and prevention/screening for cardiac diseases. The company
has gathered substantial clinical evidence and received a Class II
CE mark and 510(k) clearance. inHEART started commercializing its
SaaS solution in 2022 and is rapidly growing its user base in
Europe and the U.S., now available in over 140 hospitals. The
company uses its vast amount of annotated clinical data to train
powerful predictive AI software to prevent and screen for sudden
cardiac death, stroke, and heart failure. These SaaS solutions will
be released in several phases, starting in 2024.” Press Contact:
Todor Jeliaskov, todor.jeliaskov@inheartmedical.com, 05 35 38 19
72
About CODOC
CODOC is a healthtech company specializing in the development of
business applications and the deployment of healthcare data
warehouses. CODOC supports healthcare and research stakeholders in
the reuse of healthcare data to accelerate research and improve
patient care. Created in 2017, CODOC's solutions have proved their
worth and are now deployed in some fifteen French hospitals and
cited in over a hundred scientific publications. To find out more:
www.codoc.co Press contact: Mélissa Carballeda, +33 6 78 37 23 36,
melissa@codoc.co
About Qairnel
Qairnel is a spin-off from Inria and the Paris Brain Institute.
We launched docteurmemo.fr, the first digital clinic dedicated to
memory impairments. Patients benefit from online screening tools
and coordinated care pathways which rely on a network of partnering
healthcare professionals. Generative AI tools predict the
progression trajectory of each patient, and are used therefore to
operate precision clinical trials faster and at lower costs with
patients with well characterized progression profiles. Press
contact: stanley.durrleman@qairnel.com
About Neurometers
Neurometers is a start-up company - a spin-off from the Institut
du Cerveau in Paris, on the Pitié-Salpêtrière campus (APHP and
Sorbonne University) - created as a result of the cognitive
neuroscience work on consciousness carried out by Lionel Naccache
(Sorbonne University, APHP) and Jacobo Sitt (INSERM) on healthy
humans and patients suffering from disorders of consciousness. From
an individual's electroencephalogram (EEG), cerebral signatures of
cognition and state of consciousness are calculated and then used
to train machine learning algorithms to identify a specific
cognitive process or state of consciousness. Several studies have
demonstrated the medical relevance of these algorithms, both in the
field of consciousness disorders and in Alzheimer's disease. Press
contact: lionel.naccache@icm-institute.org and
jacobo.sitt@icm-institute.org
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124806612/en/
Dassault Systèmes
Press contact: arnaud.malherbe@3ds.com
Destiny Media Technologies (TSXV:DSY)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Destiny Media Technologies (TSXV:DSY)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
